Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Roche's Genentech loses appeals court bid over Amgen Mvasi, Bloomberg reports » 10:46
07/06/20
07/06
10:46
07/06/20
10:46
RHHBY

Roche

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$262.61 /

+4.21 (+1.63%)

Roche's (RHHBY)…

Roche's (RHHBY) Genentech unit lost its appeals court bid to halt Amgen's (AMGN) biosimilar of the cancer drug Avastin, according to Bloomberg Law. Genentech had argued that Amgen didn't provide adequate notice, as required by law, before it began selling the biosimilar Mvasi. The U.S. Court of Appeals for the Federal Circuit ruled Monday that adequate notice had been given, the report notes. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
AMGN Amgen
$262.61 /

+4.21 (+1.63%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

Periodicals
Roche unit loses bid to halt sales of Amgen's Avastin biosimilar, Bloomberg says » 09:24
07/06/20
07/06
09:24
07/06/20
09:24
AMGN

Amgen

$258.40 /

+3.24 (+1.27%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche's (RHHBY)…

Roche's (RHHBY) Genentech unit lost an appeal ruling over Amgen's (AMGN) MVASI, according to Bloomberg.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

Thursday
Recommendations
Citi sees 'considerable amount of investor interest' coming back to Amgen » 06:45
07/02/20
07/02
06:45
07/02/20
06:45
AMGN

Amgen

$255.16 /

+19.24 (+8.16%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal believes investors "can be relieved" now that the federal circuit ruled in favor of Amgen about the Enbrel intellectual property case with Sandoz. Many investors were concerned about this given that Enbrel is a core product for the company, and a loss in this case would have meant immediate downward revision in near-term estimates, Bansal tells investors in a research note. The analyst expects a "considerable amount of investor interest" will come back to Amgen with this "key overhang" removed. The company has multiple pipeline readouts in the second half of 2020 and also a good Phase 2 pipeline building up, says Bansal, who keeps a Buy rating on the shares.

ShowHide Related Items >><<
AMGN Amgen
$255.16 /

+19.24 (+8.16%)

AMGN Amgen
$255.16 /

+19.24 (+8.16%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
AMGN Amgen
$255.16 /

+19.24 (+8.16%)

AMGN Amgen
$255.16 /

+19.24 (+8.16%)

AMGN Amgen
$255.16 /

+19.24 (+8.16%)

AMGN Amgen
$255.16 /

+19.24 (+8.16%)

Over a week ago
Recommendations
Amgen appeal rules in favor of patent validity, says Piper Sandler » 11:57
07/01/20
07/01
11:57
07/01/20
11:57
AMGN

Amgen

$249.47 /

+13.55 (+5.74%)

, NVS

Novartis

$87.78 /

+0.375 (+0.43%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond maintained an Overweight rating on Amgen (AMGN) shares after the company won an appeal against Sandoz's (NVS) long-standing challenge of Amgen's Enbrel patents. Raymond has long modeled success on this front for Amgen and assumes exclusivity to 2029. The analyst's price target remains $255.

ShowHide Related Items >><<
NVS Novartis
$87.78 /

+0.375 (+0.43%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
NVS Novartis
$87.78 /

+0.375 (+0.43%)

07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
NVS Novartis
$87.78 /

+0.375 (+0.43%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

NVS Novartis
$87.78 /

+0.375 (+0.43%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

NVS Novartis
$87.78 /

+0.375 (+0.43%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

NVS Novartis
$87.78 /

+0.375 (+0.43%)

AMGN Amgen
$249.47 /

+13.55 (+5.74%)

Hot Stocks
Amgen announces appeals court affirms validity of Enbrel patents » 11:53
07/01/20
07/01
11:53
07/01/20
11:53
AMGN

Amgen

$248.37 /

+12.45 (+5.28%)

, NVS

Novartis

$87.63 /

+0.225 (+0.26%)

Amgen (AMGN) announced…

Amgen (AMGN) announced that the United States Court of Appeals for the Federal Circuit has held in Amgen's favor on the validity of two patents that describe and claim Enbrel and methods for making it. Specifically, the appellate court affirmed an August 9, 2019 decision by the United States District Court for the District of New Jersey that had upheld the validity of two patents asserted against Sandoz (NVS) based on Sandoz's biosimilar of Enbrel. The patent infringement action was brought against Sandoz by Amgen affiliates Immunex Corporation and Amgen Manufacturing, Limited, along with the owner and licensor of the two patents, Hoffmann-La Roche Inc. "Before trial, Sandoz acknowledged its biosimilar etanercept infringes seven claims of U.S. Patent Nos. 8,063,182 and 8,163,522," Amgen stated. On October 8, 2019, by stipulation of Amgen and Sandoz, the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz's etanercept product.

ShowHide Related Items >><<
NVS Novartis
$87.63 /

+0.225 (+0.26%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
NVS Novartis
$87.63 /

+0.225 (+0.26%)

07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
NVS Novartis
$87.63 /

+0.225 (+0.26%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

NVS Novartis
$87.63 /

+0.225 (+0.26%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

NVS Novartis
$87.63 /

+0.225 (+0.26%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

NVS Novartis
$87.63 /

+0.225 (+0.26%)

AMGN Amgen
$248.37 /

+12.45 (+5.28%)

Recommendations
Amgen patent win worth $5-$12 per share, says Mizuho » 11:24
07/01/20
07/01
11:24
07/01/20
11:24
AMGN

Amgen

$248.72 /

+12.8 (+5.43%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed believes today's favorable U.S. Court of Appeals for the Federal Circuit decision in the ongoing litigation with Sandoz on Enbrel is worth $5-$12 per share for Amgen. The stock in morning trading is up $12.69 to $248.55. Consensus had already granted Enbrel near full credit for its long-term intellectual property, so Amgen's valuation is unlikely to go much higher from here, Syed tells investors in a research. A move higher beyond today's rally would suggest removal of an overhang and a re-rating of Amgen's current trading multiple, says the analyst, who keeps a Neutral rating on the shares with a $215 price target.

ShowHide Related Items >><<
AMGN Amgen
$248.72 /

+12.8 (+5.43%)

AMGN Amgen
$248.72 /

+12.8 (+5.43%)

07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
AMGN Amgen
$248.72 /

+12.8 (+5.43%)

AMGN Amgen
$248.72 /

+12.8 (+5.43%)

AMGN Amgen
$248.72 /

+12.8 (+5.43%)

AMGN Amgen
$248.72 /

+12.8 (+5.43%)

Recommendations
Court ruling removes overhang for Amgen, says Goldman Sachs » 11:10
07/01/20
07/01
11:10
07/01/20
11:10
AMGN

Amgen

$248.55 /

+12.63 (+5.35%)

Goldman Sachs analyst…

Goldman Sachs analyst Terence Flynn maintains a Conviction Buy rating and $275 price target on Amgen following an appeals court ruling in favor of Amgen in an appeal challenging the validity of Enbrel's patents. The analyst said this litigation has been an overhang for Amgen, and views the decision as "an important clearing event" for Amgen, noting that Enbrel represents and estimated ~20% of 2020 revenue.

ShowHide Related Items >><<
AMGN Amgen
$248.55 /

+12.63 (+5.35%)

AMGN Amgen
$248.55 /

+12.63 (+5.35%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
AMGN Amgen
$248.55 /

+12.63 (+5.35%)

AMGN Amgen
$248.55 /

+12.63 (+5.35%)

AMGN Amgen
$248.55 /

+12.63 (+5.35%)

AMGN Amgen
$248.55 /

+12.63 (+5.35%)

Recommendations
Amgen win on Enbrel patent removes key overhang, says Jefferies » 11:09
07/01/20
07/01
11:09
07/01/20
11:09
AMGN

Amgen

$248.09 /

+12.17 (+5.16%)

, NVS

Novartis

$87.82 /

+0.415 (+0.47%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee said news that Amgen (AMGN) has formally won the Enbrel litigation as Novartis' (NVS) Sandoz unit has failed again to invalidate the patents in its appeal removes a key overhang. The news leaves "a clean story" with several potential blockbuster assets in the pipeline, according to Yee, who identifies three underappreciated catalysts for Amgen: the pivotal Phase 2 AMG510 KRAS lung cancer data that could come in September or October; the Phase 3 tezepelumab asthma data at year-end; and the Phase 3 omecamtiv heart failure data that is also upcoming. Yee keeps a Buy rating on Amgen with a $285 price target.

ShowHide Related Items >><<
NVS Novartis
$87.82 /

+0.415 (+0.47%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
NVS Novartis
$87.82 /

+0.415 (+0.47%)

07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
NVS Novartis
$87.82 /

+0.415 (+0.47%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

NVS Novartis
$87.82 /

+0.415 (+0.47%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

NVS Novartis
$87.82 /

+0.415 (+0.47%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

NVS Novartis
$87.82 /

+0.415 (+0.47%)

AMGN Amgen
$248.09 /

+12.17 (+5.16%)

Periodicals
Appeals court upholds Amgen patents on Enbrel, Bloomberg reports » 10:46
07/01/20
07/01
10:46
07/01/20
10:46
AMGN

Amgen

$246.22 /

+10.295 (+4.36%)

, NVS

Novartis

$87.68 /

+0.275 (+0.31%)

An appeals court has…

An appeals court has ruled in favor of Amgen (AMGN) over patents for rheumatoid arthritis drug Enbrel, allowing it to block a biosimilar from Novartis' (NVS) Sandoz until 2029, Bloomberg's Susan Decker reports, citing the ruling. Sandoz, which contended the patents should not have been is issued, is looking to sell a copycat version of the drug named Erelzi. Reference Link

ShowHide Related Items >><<
NVS Novartis
$87.68 /

+0.275 (+0.31%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
NVS Novartis
$87.68 /

+0.275 (+0.31%)

07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
NVS Novartis
$87.68 /

+0.275 (+0.31%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

NVS Novartis
$87.68 /

+0.275 (+0.31%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

NVS Novartis
$87.68 /

+0.275 (+0.31%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

NVS Novartis
$87.68 /

+0.275 (+0.31%)

AMGN Amgen
$246.22 /

+10.295 (+4.36%)

Hot Stocks
Amgen jumps after winning appeal ruling upholding Enbrel patents » 10:36
07/01/20
07/01
10:36
07/01/20
10:36
AMGN

Amgen

$245.18 /

+9.26 (+3.93%)

, NVS

Novartis

$87.57 /

+0.165 (+0.19%)

Amgen (AMGN) shares are…

Amgen (AMGN) shares are higher in morning trading after it was reported that the U.S. Court of Appeals for the Federal Circuit upheld patents for rheumatoid arthritis drug Enbrel, blocking a biosimilar version that Novartis (NVS) seeks to sell until 2029. Novartis' Sandoz unit is seeking to sell its own version of Enbrel, called Erelzi, and had argued that the patents should not have been issued to Amgen, according to Bloomberg's account of the case. In morning trading, Amgen shares are up $10.76, or 4.5%, to $246.62.

ShowHide Related Items >><<
NVS Novartis
$87.57 /

+0.165 (+0.19%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
NVS Novartis
$87.57 /

+0.165 (+0.19%)

07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
NVS Novartis
$87.57 /

+0.165 (+0.19%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

NVS Novartis
$87.57 /

+0.165 (+0.19%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

NVS Novartis
$87.57 /

+0.165 (+0.19%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

NVS Novartis
$87.57 /

+0.165 (+0.19%)

AMGN Amgen
$245.18 /

+9.26 (+3.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.